경장영양 제제 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Enteral Feeding Formulas Market reached USD 7 billion in 2023 and is expected to grow at a CAGR of 7.1% from 2024 to 2032. Enteral feeding formulas are specialized liquid nutrition products designed for individuals who cannot consume food orally due to medical conditions such as swallowing difficulties, gastrointestinal disorders, or neurological impairments. These formulas are typically administered via a feeding tube that delivers nutrients directly to the stomach or small intestine.

The market includes a variety of formulas, such as standard formulas, disease-specific formulas, elemental formulas, semi-elemental formulas, and others. The standard formulas segment held the largest market share, contributing USD 3.6 billion in 2023. Their broad usage across diverse patient populations, along with their cost-effectiveness, makes them a preferred choice. The easy availability and affordability of these complete nutritional formulas, suitable for both hospital and home care settings, are expected to drive significant growth in this segment over the coming years.

The market is also divided by age group, with the adult segment leading in 2023, accounting for 82.2% of the total market revenue. This trend is primarily driven by the increasing number of elderly individuals who often require enteral feeding due to various health challenges associated with aging. As healthcare systems adapt to meet the nutritional needs of an aging population, the demand for enteral nutrition is expected to continue growing, further boosting this segment.

By end use, the enteral feeding formula market is segmented into hospitals, long-term care facilities, home care settings, and nursing homes. The hospital segment, valued at USD 3.2 billion in 2023, plays a key role in the market's growth. Increasing awareness about the importance of proper nutrition in patient recovery is driving hospitals to adopt enteral feeding solutions. Enteral nutrition is known to speed up healing, reduce complications, and shorten recovery times, leading to its growing use in hospitals.

In the U.S., the enteral feeding formula market was valued at USD 2.8 billion in 2023, with an anticipated growth rate of 7.2% CAGR during the forecast period. The U.S. market is characterized by continuous innovations in product formulations, including lactose-free, gluten-free, and low-residue options, catering to a wide range of patient needs. The aging population in the U.S. is a major factor driving demand, as older adults often struggle with conditions that prevent them from eating orally. This demographic trend is expected to sustain long-term growth in the enteral feeding formula market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising geriatric population and chronic disease prevalence
    • 3.2.1.2 Growing demand for neonatal and preterm enteral feeding
    • 3.2.1.3 Increasing demand for enteral feeding in home care settings
    • 3.2.1.4 Shifting trend toward consumption of disease-specific formulas
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High costs associated with enteral feeding
    • 3.2.2.2 Risk of complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis
  • 3.6.1 By region
  • 3.6.2 By product
• 3.7 Consumer behavior analysis
• 3.8 Future market trends
• 3.9 Patent analysis
• 3.10 Pipeline analysis
• 3.11 Clinical trial landscape
• 3.12 Gap analysis
• 3.13 Porter's analysis
• 3.14 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Standard formulas
• 5.3 Disease specific formulas
• 5.4 Elemental formulas
• 5.5 Semi-elemental formulas
• 5.6 Other formulas

Chapter 6 Market Estimates and Forecast, By Stage, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Adults
• 6.3 Pediatric

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oncology
• 7.3 Gastrointestinal diseases
• 7.4 Neurological disorders
• 7.5 Diabetes
• 7.6 Critical care
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Long term care facilities
• 8.4 Home care settings
• 8.5 Nursing homes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 B. Braun Melsungen AG
• 10.3 Baxter International
• 10.4 Danone S.A.
• 10.5 Fresenius Kabi
• 10.6 Functional Formularies
• 10.7 Hormel Health Labs
• 10.8 Kate Farms
• 10.9 Medtrition
• 10.10 Meiji Holdings
• 10.11 Nestle
• 10.12 NutriMedical
• 10.13 Real Food Blends
• 10.14 Vegenat Healthcare
• 10.15 Victus